相关实验视频

Updated: Jan 16, 2026

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

在IBS-D大鼠中,电可以通过调节巨细胞衍生的外体MiR-149-5p恢复肠道粘膜屏障

Yujun Hou¹, Fangli Luo^1,2, Kai Wang³

¹School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Frontiers in immunology

|October 3, 2025

概括

电针 (EA) 疗法通过调节细胞衍生的外体微RNAs (miRNAs) 来改善腹占主导地位的刺激性肠综合征 (IBS-D) 鼠的肠道屏障功能. 具体来说,MC-EXO miR-149-5p 在这种治疗过程中起着关键作用.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
神经科学是一个神经科学.

背景情况:

肠道屏障功能障碍是腹占主导地位的刺激性肠综合征 (IBS-D) 的主要原因.
乳腺细胞是IBS-D肠道屏障功能障碍的关键调解者.
电针 (EA) 显示出恢复肠粘膜屏障功能的潜力.

研究的目的:

在IBS-D大鼠中研究杆细胞衍生的外体微RNA (MC-EXO小RNA) 在EA介导的肠壁修复中的作用.
阐明涉及的特定miRNA及其作用机制.

主要方法:

由慢性不可预测的轻度压力和Senna管理引起的IBS-D大鼠模型.
用EA,巨细胞/外体细胞调节剂和腺相关病毒 (AAV) 治疗.
通过各种技术 (qPCR,TEM,IHC,ELISA,WB) 评估内脏疼痛,腹,结肠病理,巨细胞激活和肠道屏障完整性 (包括紧密的结节).
对MC-EXO进行miRNA测序,GO和KEGG丰富分析.
使用Caco-2细胞进行体外研究,以评估miRNA对透性和紧结蛋白的影响.

主要成果:

EA治疗通过降低CRF和CRF-R1的调节,抑制巨细胞激活,并增强紧结蛋白表达来缓解IBS-D症状.
这些有益效应是由CRF/杆细胞激动剂和外体酶抑制剂调节的.
在接受EA治疗的老鼠中,MiRNA测序确定了miR-149-5p和miR-22-5p的显著变化,这些变化丰富了紧密的结路.
在体外和体内实验表明,miR-149-5p对肠道的透性和紧密结合的完整性产生负面影响,抵消EA的保护作用.

结论:

结核细胞衍生异位体miR-149-5p是IBS-D大鼠EA介导的肠壁修复的关键调节者.
在IBS-D患者中,EA疗法通过调节MC-EXO微RNA来恢复肠道屏障功能.
准MC-EXO miRNAs是IBS-D的潜在治疗策略.

关键词:

电针是一种电针.外基因组是外基因组的组成部分.刺激性肠综合征是什么意思巨细胞巨细胞微型鼻子微型鼻子紧密的结节紧密的结节

更多相关视频

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...